Acute coronary syndromes: should women receive less antithrombotic medication than men?
A recent meta-analysis of all randomised trials assessing the efficacy and safety of glycoprotein IIb/IIIa agents with acute coronary syndromes showed that there was a significant interaction with sex. Explaining this difference requires an analysis of whether it has any pathophysiological basis, whether antithrombotic medications are indeed less efficacious in women in different clinical situations, and whether there are any specific reasons that may have led to the provocative results of the meta-analysis.
Danchin
N
N
Cardiologie, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France. nicolas.danchin@egp.ap-hop-paris.fr
D000208:Acute Disease; D003327:Coronary Disease / Q000188:drug therapy*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000139:chemically induced / Q000517:prevention & control; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012737:Sex Factors; D013577:Syndrome
D005343:Fibrinolytic Agents; D019039:Platelet Glycoprotein GPIIb-IIIa Complex